Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.

Yang MQ, Elnitski L.

PLoS One. 2016 Oct 27;11(10):e0163353. doi: 10.1371/journal.pone.0163353. eCollection 2016 Oct 27.

2.

Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.

Hughes CS, McConechy MK, Cochrane DR, Nazeran T, Karnezis AN, Huntsman DG, Morin GB.

Sci Rep. 2016 Oct 7;6:34949. doi: 10.1038/srep34949.

3.

KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.

Zhao H, Guo E, Hu T, Sun Q, Wu J, Lin X, Luo D, Sun C, Wang C, Zhou B, Li N, Xia M, Lu H, Meng L, Xu X, Hu J, Ma D, Chen G, Zhu T.

Oncotarget. 2016 Jul 12;7(28):43924-43938. doi: 10.18632/oncotarget.9721.

4.

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.

Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ.

Ann Oncol. 2016 Apr;27 Suppl 1:i4-i10. doi: 10.1093/annonc/mdw083.

PMID:
27141069
5.

Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma.

Ahmed I, Karedath T, Andrews SS, Al-Azwani IK, Mohamoud YA, Querleu D, Rafii A, Malek JA.

Oncotarget. 2016 Jun 14;7(24):36366-36381. doi: 10.18632/oncotarget.8917.

6.

Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.

Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z, Sun J.

Oncotarget. 2016 May 31;7(22):32433-48. doi: 10.18632/oncotarget.8653.

7.

A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma.

Sun CY, Su TF, Li N, Zhou B, Guo ES, Yang ZY, Liao J, Ding D, Xu Q, Lu H, Meng L, Wang SX, Zhou JF, Xing H, Weng DH, Ma D, Chen G.

Oncotarget. 2016 Jan 19;7(3):3245-54. doi: 10.18632/oncotarget.6569.

8.

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, Tanyi JL, Galanis A, Kakolyris S, Trypsianis G, Coukos G, Sandaltzopoulos R.

Biomed Res Int. 2015;2015:712438. doi: 10.1155/2015/712438. Epub 2015 Sep 13.

9.

Genome-wide analysis of microRNA and mRNA expression signatures in cancer.

Li MH, Fu SB, Xiao HS.

Acta Pharmacol Sin. 2015 Oct;36(10):1200-11. doi: 10.1038/aps.2015.67. Epub 2015 Aug 24. Review.

10.

Derivation of a fifteen gene prognostic panel for six cancers.

Khirade MF, Lal G, Bapat SA.

Sci Rep. 2015 Aug 14;5:13248. doi: 10.1038/srep13248.

11.

Prediction of resistance to chemotherapy in ovarian cancer: a systematic review.

Lloyd KL, Cree IA, Savage RS.

BMC Cancer. 2015 Mar 11;15:117. doi: 10.1186/s12885-015-1101-8. Review.

12.

Proteomics of ovarian cancer: functional insights and clinical applications.

Elzek MA, Rodland KD.

Cancer Metastasis Rev. 2015 Mar;34(1):83-96. doi: 10.1007/s10555-014-9547-8. Review.

13.

Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.

Olsen L, Campos B, Winther O, Sgroi DC, Karger BL, Brusic V.

BMC Med Genomics. 2014;7 Suppl 3:S2. doi: 10.1186/1755-8794-7-S3-S2. Epub 2014 Dec 8.

14.

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.

Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I, Győrffy B.

BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.

15.

Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.

Vargas HA, Miccò M, Hong SI, Goldman DA, Dao F, Weigelt B, Soslow RA, Hricak H, Levine DA, Sala E.

Radiology. 2015 Mar;274(3):742-51. doi: 10.1148/radiol.14141477. Epub 2014 Nov 10.

16.

Ovarian cancer biomarker discovery based on genomic approaches.

Lee JY, Kim HS, Suh DH, Kim MK, Chung HH, Song YS.

J Cancer Prev. 2013 Dec;18(4):298-312. Review.

17.

FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.

Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, Jean C, Chen XL, Ward KK, Schlaepfer DD.

Mol Cancer Ther. 2014 Aug;13(8):2050-61. doi: 10.1158/1535-7163.MCT-13-1063. Epub 2014 Jun 4.

18.

Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types.

Yang Y, Han L, Yuan Y, Li J, Hei N, Liang H.

Nat Commun. 2014;5:3231. doi: 10.1038/ncomms4231.

19.

Gynecologic biopsy for molecular profiling: a review for the interventional radiologist.

Corr BR, Behbakht K, Spillman MA.

Semin Intervent Radiol. 2013 Dec;30(4):417-24. doi: 10.1055/s-0033-1359738. Review.

20.

Ovarian cancer: genomic analysis.

Wei W, Dizon D, Vathipadiekal V, Birrer MJ.

Ann Oncol. 2013 Dec;24 Suppl 10:x7-15. doi: 10.1093/annonc/mdt462. Review.

Supplemental Content

Support Center